Alworth W L, Slaga T J
Carcinogenesis. 1985 Apr;6(4):487-93. doi: 10.1093/carcin/6.4.487.
Varying doses of ellipticine (EL), flavone (FL), or 7,8-benzoflavone (78BF) were applied to mouse skin 5 min before an initiating dose of 10 nmol 7,12-dimethylbenz[a]anthracene (DMBA), 47.5 nmol 7,14-dimethylbenzo[a,h]anthracene (DDBA), or 200 nmol dibenzo[a,h]anthracene (DBA) and the development of skin tumors in the mice then promoted by topical applications of 2 micrograms 12-O-tetradecanoylphorbol-13-acetate (TPA). As expected, treatment with 78BF (37 nmol or 370 nmol) markedly inhibited the skin tumor initiation by DMBA (greater than 70%). High doses of FL (4500 nmol) or EL (410 nmol) also inhibited DMBA tumorigenesis (52% and 82%, respectively) but lower doses of FL (450 nmol) or EL (4.1 nmol) stimulated DMBA tumorigenesis (greater than 40%). As was the case with DMBA initiation, the higher doses of FL or EL inhibited DDBA skin tumorigenesis and the lower doses of these two modifiers stimulated the DDBA tumorigenesis. In contrast with the results with DMBA initiation, treatment with 78BF (370 nmol or 3700 nmol) slightly enhanced DDBA tumorigenesis (22% and 6%, respectively). Treatment with EL and FL at all doses tested stimulated DBA tumorigenesis (range 4-51%), while treatment with 370 nmol 78BF slightly stimulated DBA tumorigenesis (19%) and treatment with 3700 nmol slightly inhibited DBA tumorigensis (9%). The effects of a range of 78BF doses upon skin tumor initiation by 40 nmol DMBA were also investigated. While all doses of 78BF tested (0.37-370 nmol) inhibited the DMBA tumorigenesis, the dose response was not linear; treatment with 3.7 nmol 78BF resulted in more papillomas per mouse (12.20) than did treatment with either 0.37 nmol 78BF (8.70) or 37 nmol 78BF (5.97). It is concluded that modifiers such as 78BF, FL and EL may have a variable, dose-dependent effect upon skin tumor initiation by carcinogenic polycyclic arylhydrocarbons. Some implications of this proposal are discussed.
在给予起始剂量的10 nmol 7,12-二甲基苯并[a]蒽(DMBA)、47.5 nmol 7,14-二甲基苯并[a,h]蒽(DDBA)或200 nmol二苯并[a,h]蒽(DBA)前5分钟,将不同剂量的玫瑰树碱(EL)、黄酮(FL)或7,8-苯并黄酮(78BF)涂抹于小鼠皮肤,然后通过局部涂抹2微克12-O-十四烷酰佛波醇-13-乙酸酯(TPA)促进小鼠皮肤肿瘤的发生。正如预期的那样,用78BF(37 nmol或370 nmol)处理可显著抑制DMBA引发的皮肤肿瘤(大于70%)。高剂量的FL(4500 nmol)或EL(410 nmol)也可抑制DMBA致瘤作用(分别为52%和82%),但低剂量的FL(450 nmol)或EL(4.1 nmol)可刺激DMBA致瘤作用(大于40%)。与DMBA起始情况相同,较高剂量的FL或EL可抑制DDBA皮肤肿瘤发生,而这两种调节剂的低剂量可刺激DDBA肿瘤发生。与DMBA起始的结果相反,用78BF(370 nmol或3700 nmol)处理可轻微增强DDBA致瘤作用(分别为22%和6%)。在所有测试剂量下,用EL和FL处理均可刺激DBA致瘤作用(范围为4 - 51%),而用370 nmol 78BF处理可轻微刺激DBA致瘤作用(19%),用3700 nmol处理可轻微抑制DBA致瘤作用(9%)。还研究了一系列78BF剂量对40 nmol DMBA引发皮肤肿瘤的影响。虽然所有测试剂量的78BF(0.37 - 370 nmol)均抑制了DMBA致瘤作用,但剂量反应并非呈线性;用3.7 nmol 78BF处理的每只小鼠产生的乳头状瘤(12.20个)比用0.37 nmol 78BF(8.70个)或37 nmol 78BF(5.97个)处理的更多。得出的结论是,诸如78BF、FL和EL等调节剂可能对致癌多环芳烃引发的皮肤肿瘤产生可变的、剂量依赖性的影响。讨论了该提议的一些影响。